GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

A new study provides important insight into how amyloid-beta and tau proteins impact brain activity and possibly contribute to cognitive decline in Alzheimer's disease.

The clearance adds a Centiloid scale tool to GE Healthcare’s Mim software to help clinicians determine the density of amyloid ...

GE Healthcare's MIM Software announces the receipt of FDA clearance for its Centiloid scaling tool to perform PET-based ...

The GE HealthCare imaging tool is coming out as pharma companies release new therapies onto the market to help treat the ...

Researchers discover how amyloid-β and tau pathologies interact to drive early neurophysiological changes and cognitive ...

Researchers have shed new light on how amyloid-beta and tau proteins influence brain activity and cognitive decline in ...

GE HealthCare’s MIM Software receives US FDA clearance of new Centiloid scaling tool to quantify amyloid plaque in brain imaging: Chicago Thursday, September 19, 2024, 12:00 Hrs ...

A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...

With FDA 510(k) clearance, MIMneuro may perform positron emission tomography-based imaging analysis of amyloid plaque, GE ...

MIM Software’s Centiloid scaling tool is approved for positron emission tomography (PET)-based amyloid imaging analysis and ...